Sensyne Health PLC - clinical technology company - Signs a five year non-exclusive strategic research agreement with Royal Wolverhampton NHS Trust. The agreement will enable the ethical application of clinical artificial intelligence research to improve patient care and accelerate research into new medicines. The trust will receive 1.4 million shares in Sensyne Health, representing 0.9% of the existing issued share capital. Royal Wolverhampton NHS Trust will also receive from Sensyne an investment of up to GBP250,000 per year over the five-year term of the contract for specific investments in NHS information technology to enable the curation and analysis of data.
Current stock price: 156.25 pence, down 1.7% on Wednesday
Year-to-date change: up 39%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
